USRE42645E1 - Nutritional or therapeutic compositions and methods to increase bodily glutathione levels - Google Patents

Nutritional or therapeutic compositions and methods to increase bodily glutathione levels Download PDF

Info

Publication number
USRE42645E1
USRE42645E1 US11/371,804 US37180406A USRE42645E US RE42645 E1 USRE42645 E1 US RE42645E1 US 37180406 A US37180406 A US 37180406A US RE42645 E USRE42645 E US RE42645E
Authority
US
United States
Prior art keywords
composition
selenium
glutathione
mammal
cystine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/371,804
Inventor
Albert Crum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proimmune Co LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/371,804 priority Critical patent/USRE42645E1/en
Priority to US13/184,041 priority patent/US20120029082A1/en
Application granted granted Critical
Publication of USRE42645E1 publication Critical patent/USRE42645E1/en
Assigned to THE PROIMMUNE COMPANY, LLC reassignment THE PROIMMUNE COMPANY, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRUM, ALBERT, DR.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to nutritional or therapeutic compositions useful for treating mammals to increase their body content of glutathione above a pretreatment level thereby to enhance the immune activity of the treated mammal. More specifically, it relates to compositions containing a selenium compound together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine.
  • Glutathione is a tripeptide and a major reducing agent in the mammalian body. Its chemical structure is:
  • ROS reactive oxygen species
  • RNS reactive nitrogen species
  • Mammalian cells have numerous mechanisms to eliminate these damaging free radicals and reactive species.
  • One such mechanism includes the glutathione system, which plays a major role in direct destruction of reactive oxygen compounds and also plays a role in the body's defense against infection.
  • glutathione One of the most important contributions of glutathione to mammalian health is its participation in the proper functioning of the immune system to respond to infection or other types of trauma. It is known that weakening of the immune system caused by infection or other traumas occurs concurrently with depletion of glutathione in body tissues. It is known, also, that such weakening can be reversed by replenishing the supply of glutathione. It is believed that glutathione accomplishes its salutary effects by protecting immune cells against the ravages of oxidizing agents and free radicals.
  • compositions and methods to aid in elimination of damaging free radicals and reactive oxygen and nitrogen species.
  • One possible mechanism for achieving this may be through enhancement of glutathione levels in patients utilizing precursors for glutathione synthesis.
  • the mucous membrane is the membrane which lines those body passages which communicate directly or indirectly with the exterior.
  • the important parts of the mucous membrane are those portions which line the oral passage, the nose, the anus and the vagina since the compositions are intended for sublingual, buccal, nasal, anal and or vaginal delivery.
  • Oral delivery by sublingual or buccal routes is much preferred because of its convenience. Such delivery may be, for example, in the form of pills, lozenges and tablets which may be retained in the mouth until dissolved. In rare instances, parenteral delivery may be utilized, but this is normally not necessary.
  • compositions of this invention are:
  • the separate components serve as precursors for the metabolic formation of glutathione after they have been transported across the mucous membrane.
  • compositions may be used alone but, normally they will be employed in association with one or more non-toxic pharmaceutically acceptable carriers appropriate to the method of administration.
  • compositions will be utilized to increase the formation of glutathione and thus to enhance the immune activity of a mammal in need of such treatment.
  • the effect of the treatment is such that after the treatment, the mammal will be more resistant to microbial infection or other trauma adversely affecting immune activity than before such treatment.
  • compositions are useful to treat a wide variety of diseases associated with the presence of excess free radical or reactive oxygen or nitrogen species. These include, for example, cancer, Alzheimer's disease, arteriosclerosis, rheumatoid arthritis and other autoimmune diseases, cachexia, coronary artery disease, chronic fatigue syndrome, AIDS and others as will be apparent to the skilled artisan.
  • compositions described and claimed herein will contain components suitable for the anabolic production of glutathione once they have been transported through the mucous membrane.
  • the precursors of glutathione are glutamic acid, cystine and glycine.
  • the proposed components are amphoteric and therefore may be employed as non-toxic metal salts or acid addition salts.
  • the salts are alkalic or alkaline earth metal salts, preferably sodium, potassium or calcium salts.
  • Suitable acid addition salts include salts of hydrochloric, phosphoric and citric acid.
  • amino acids may also be employed in the form of certain of their derivatives including esters and anhydrides which before or after transport through the mucous membrane will be modified into the form in which they will be joined together to form glutathione.
  • glutamic acid cystine, glycine
  • the sulfur containing amino acid in the compositions of this invention is cystine.
  • the sulfur containing amino acid moiety in glutathione is cysteine.
  • the latter contains a sulfhydryl group. In the former molecule, two cysteine molecules are joined via a disulfide bond.
  • cystine is used in the compositions of this invention. Upon reductive cleavage of the disulfide bridge, two molecules of cysteine are formed. Thus each molecule of cystine is capable of forming two molecules, of cysteine, each of which will join with glutamic acid and glycine to form two molecules of glutathione.
  • the only component in the novel compositions of this invention which may be toxic is selenium. Accordingly, in providing dosage units for mammalian administration by any selected route, the limiting factor is to avoid treatment either with single or multiple dosage units at such levels that the total delivery of selenium is close to its toxic limit.
  • the recommended daily dosage for humans therefore ranges from 10 to 75 ⁇ g per day.
  • the range may be generally higher but will, of course, depend upon the animal and its size.
  • compositions of this invention for daily delivery and the duration of the period of such delivery will depend upon the professional judgment of the physician or veterinarian in attendance. Numerous factors will be involved in that judgment such as age, body weight, physical condition of the patient or animal and the ailment or disorder being treated.
  • Selenium is one of numerous trace metals found in many foods.
  • selenium may be employed as one of several non-toxic, water soluble organic or inorganic selenium compounds capable of being absorbed through the mucosal membrane.
  • the presently preferred inorganic selenium compounds are aliphatic metal salts containing selenium in the form of selenite or selenate anions.
  • organic selenium compounds are more preferred because they are normally less toxic than inorganic compounds.
  • Other selenium compounds which may be mentioned by way of example include selenium cystine, selenium methionine, mono- and di-seleno carboxylic acids with about seven to eleven carbon atoms in the chain.
  • Seleno Amino acid chelates are also useful. Any of these selenium compounds may be considered for use in the present invention as selenium precursors.
  • selenium as employed in the composition be capable of transport through the mucosal membrane of the patient under treatment. For this reason, water insoluble selenium compounds are not generally useful.
  • selenium is sometimes used hereinafter to include any of the various water soluble selenium products which can be transported through the mucosal membrane in the practice of this invention. It will be understood, however, that the particular forms of selenium compounds set forth herein are not to be considered limitative. Other selenium compounds, which exhibit the desired activity and are compatible with the other components in the mixture and are non-toxic, can be used in the practice of the invention. Many of them are available commercially.
  • the amount of selenium precursor employed in the novel compositions is only enough to provide a catalytic quantity of the element to activate the glutathione system.
  • the catalytic quantity of selenium precursor utilized in the compositions of this invention is such that it will produce either in one dosage unit or in multiple dosage units sufficient elemental selenium to promote the production and activation of glutathione. Typically, this will be at or near the recommended daily allowance of selenium for the individual mammal under treatment. This amount will be well below the toxicity limit for elemental selenium.
  • a representative range of catalytic quantities of selenium precursors is set forth in the present application in paragraph [0026] on page 6, as shown to be effective based on the age of the individual.
  • the presently preferred method of transdermal delivery for the novel compositions is oral, either sublingual or buccal. It is convenient to provide dosage units for such delivery in the form of pills, lozenges or tablets such as gelled tablets which will slowly dissolve in the mouth.
  • Nasal delivery will typically be accomplished by sprays or drops. Suppositories will be useful for rectal or vaginal delivery.
  • compositions used in the method of the invention comprise a therapeutically effective amount of combined glutamic acid, cystine, glycine and a selenium precursor in a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means one that is generally recognized as safe, approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the active compounds are administered.
  • compositions which may be provided in bulk or dosage unit form are prepared in accordance with standard pharmaceutical practice and may contain excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • Sterile liquids such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil may also be useful.
  • the composition if desired, can also contain
  • Buffering agents are sometimes used in the compositions of the invention to maintain a relatively constant hydrogen ion concentration in the mouth (pH about 7.5) or other point of entry.
  • An appropriate buffering agent may be selected from numerous known reagents including, for example phosphate, carbonate and bicarbonate systems.
  • Alpha-lactalbumin is useful because of its buffering properties. Additionally, it is non-toxic, water soluble and contains appreciable amounts of the required amino acids.
  • compositions may also contain mucous membrane penetration enhancers such as sodium lauryl sulphate, sodium dodecyl sulphate, cationic surfactants such as palmitoyl DL camitine chloride, cetylpyridinium chloride, non-ionic surfactants such as polysorbate 80, polyoxyethylene 9-lauryl either, glyceryl monolaurate, polyoxyalkylenes, polyoxyethylene 20 cetyl ether, lipids such as oleic acid, bile salts such as sodium glycocholate, sodium taurocholate and related compounds.
  • mucous membrane penetration enhancers such as sodium lauryl sulphate, sodium dodecyl sulphate, cationic surfactants such as palmitoyl DL camitine chloride, cetylpyridinium chloride, non-ionic surfactants such as polysorbate 80, polyoxyethylene 9-lauryl either, glyceryl monolaurate, polyoxyalkylenes, poly
  • compositions of the invention are most conveniently utilized in dosage units for oral administration. They may be used alone but are preferably provided as tablets, suitably sublingual tablets. Such tablets may be prepared in one a day form or for intermittent use throughout the day, for example every three hours.
  • the tablets will typically weigh from about 0.5 to 5 grams and will contain a therapeutically effective amount of the essential ingredients together with the selected vehicle.
  • “Therapeutically effective” as used herein means the amount of the composition which is sufficient to achieve the desired result, i.e., enhancement of the immune system. It means that the immune system is more effective in combating infection after treatment than it was before treatment.
  • compositions of the invention can be provided in a number of different forms and at dosage levels appropriate to the individual mammal being treated.
  • tablets, elixers, solutions, emulsions, powders, capsules and other forms can be provided for one a day treatment or successive treatments on the same day for animals or humans whether male or female, whether infant, adolescent or adult.
  • the defining feature of this advantage is the amount of selenium precursor utilized since the other components are essentially non-toxic.
  • tablets and other forms of the immunoenhancing compositions can be prepared to provide any quantity of elemental selenium from less than 1 ⁇ g to 7.5 ⁇ g.
  • a tablet containing 10 ⁇ g of selenium methionine is capable of delivering 4 ⁇ g of elemental selenium
  • 7.5 ⁇ g of selenium methionine is capable of delivering 3 ⁇ g of selenium. Tablets may be given several times per day to achieve the desired immune enhancing effect.
  • a one a day tablet weighing two grams may contain 200 mg or more of the composition.
  • a similar tablet intended to be used every four hours may contain 50 mg to 100 mg or more of the therapeutically effective composition. Equivalent amounts of carrier and active components will be utilized in other compositions designed for other methods of administration.
  • EXAMPLE 1 (TABLET) Ingredients: 89 mg cystine 75 mg glycine 147 mg glutamic acid 22.5 ⁇ g polyvinylpyrolidone 61.25 mg lactose 4.5 ml alcohol SD3A-200 proof 9 mg stearic acid 42.3 mg corn starch 10 ⁇ g selenium methionine
  • EXAMPLE 2 (TABLET) Ingredients: 178 mg cystine 150 mg glycine 294 mg glutamic acid 5 ⁇ g selenium methionine 126 mg lactose 78 mg potato starch 96 mg ethyl cellulose 54 mg stearic acid

Abstract

Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.

Description

More than one application for the Reissue of U.S. Pat. No. 6,592,908 has been filed. The reissue applications are the present application and U.S. Ser. No. 11/181,001, filed Jul. 13, 2005, and issued as U.S. Pat. RE 39,734 on Jul. 17, 2007.
STATEMENT OF PRIORITY
This application is a division of U.S. Ser. No. 11/181,001, filed Jul. 13, 2005 and which issued as U.S. Pat. RE 39,734 on Jul. 17, 2007, which is a reissue of U.S. Pat. No. 6,592,908 which issued on Jul. 13, 2005 from U.S. Ser. No. 10/252,957, filed Sep. 23, 2002, the disclosures of which are hereby incorporated by reference herein.
FIELD OF THE INVENTION
This invention relates to nutritional or therapeutic compositions useful for treating mammals to increase their body content of glutathione above a pretreatment level thereby to enhance the immune activity of the treated mammal. More specifically, it relates to compositions containing a selenium compound together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine.
BACKGROUND OF THE INVENTION
Glutathione is a tripeptide and a major reducing agent in the mammalian body. Its chemical structure is:
Figure USRE042645-20110823-C00001
or, more simply
GLU-CYS-GLY
Its chemical name is glutamyl-cysteinyl-glycine.
Like many other small peptides in the mammalian body, it is not synthesized by procedures involving DNA, RNA and ribosomes. Rather, it is synthesized from the amino acids available in the body by procedures utilizing enzymes and other body components such as adenosine triphosphate as an energy source.
It is generally recognized that many disease processes are attributed to the presence of elevated levels of free radicals, reactive oxygen species (ROS) and reactive nitrogen species (RNS), such as superoxide, hydrogen peroxide, singlet oxygen, peroxynitrite, hydroxyl radicals, hypochlorous acid (and other hypohalous acids) and nitric oxide.
Mammalian cells have numerous mechanisms to eliminate these damaging free radicals and reactive species. One such mechanism includes the glutathione system, which plays a major role in direct destruction of reactive oxygen compounds and also plays a role in the body's defense against infection.
It is known that insufficient levels of glutathione may result in the onset of numerous diseases. Diseases of aging appear to be associated with a drop in glutathione levels. Moreover, since there is no evidence of transport of glutathione into cells, glutathione must be produced intra cellularly.
One of the most important contributions of glutathione to mammalian health is its participation in the proper functioning of the immune system to respond to infection or other types of trauma. It is known that weakening of the immune system caused by infection or other traumas occurs concurrently with depletion of glutathione in body tissues. It is known, also, that such weakening can be reversed by replenishing the supply of glutathione. It is believed that glutathione accomplishes its salutary effects by protecting immune cells against the ravages of oxidizing agents and free radicals.
There is a need for compositions and methods to aid in elimination of damaging free radicals and reactive oxygen and nitrogen species. One possible mechanism for achieving this may be through enhancement of glutathione levels in patients utilizing precursors for glutathione synthesis.
There is some question as to whether orally ingested glutathione is available to enhance the immune system. Since it is a tripeptide, conventional wisdom suggests that it would be hydrolyzed in the intestinal system to release the free amino acids. Even if some of the tripeptide gets through the gastrointestinal wall intact, it is questionable whether it can be absorbed as such into the individual cell, rather than being synthesized intracellularly. Some experts are of the opinion that glutathione resists hydrolysis when taken orally. In any event, it is generally acknowledged that an increase in tissue and cellular concentrations of glutathione facilitates resistance to infective agents by enhancing the immune system.
The mucous membrane is the membrane which lines those body passages which communicate directly or indirectly with the exterior. For purposes of this invention, the important parts of the mucous membrane are those portions which line the oral passage, the nose, the anus and the vagina since the compositions are intended for sublingual, buccal, nasal, anal and or vaginal delivery. Oral delivery by sublingual or buccal routes is much preferred because of its convenience. Such delivery may be, for example, in the form of pills, lozenges and tablets which may be retained in the mouth until dissolved. In rare instances, parenteral delivery may be utilized, but this is normally not necessary.
BRIEF SUMMARY OF THE INVENTION
The essential components of the compositions of this invention are:
1. A selenium precursor together with
2. Glutamic acid, cystine and glycine.
The separate components serve as precursors for the metabolic formation of glutathione after they have been transported across the mucous membrane.
The compositions may be used alone but, normally they will be employed in association with one or more non-toxic pharmaceutically acceptable carriers appropriate to the method of administration.
The compositions will be utilized to increase the formation of glutathione and thus to enhance the immune activity of a mammal in need of such treatment. The effect of the treatment is such that after the treatment, the mammal will be more resistant to microbial infection or other trauma adversely affecting immune activity than before such treatment.
Because of their ability to increase production of glutathione, the compositions are useful to treat a wide variety of diseases associated with the presence of excess free radical or reactive oxygen or nitrogen species. These include, for example, cancer, Alzheimer's disease, arteriosclerosis, rheumatoid arthritis and other autoimmune diseases, cachexia, coronary artery disease, chronic fatigue syndrome, AIDS and others as will be apparent to the skilled artisan.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, the compositions described and claimed herein will contain components suitable for the anabolic production of glutathione once they have been transported through the mucous membrane. As presently conceived, the precursors of glutathione are glutamic acid, cystine and glycine.
It will be appreciated by the skilled artisan that the proposed components are amphoteric and therefore may be employed as non-toxic metal salts or acid addition salts. Typically, the salts are alkalic or alkaline earth metal salts, preferably sodium, potassium or calcium salts. Suitable acid addition salts include salts of hydrochloric, phosphoric and citric acid.
The amino acids may also be employed in the form of certain of their derivatives including esters and anhydrides which before or after transport through the mucous membrane will be modified into the form in which they will be joined together to form glutathione.
All of this will be readily appreciated by those skilled in the art. Accordingly, when the terms glutamic acid, cystine, glycine are employed both in the specification and claims they will be understood to mean not only the products themselves, but also those derivatives which can be converted to a unit of the glutathione molecule.
The sulfur containing amino acid in the compositions of this invention is cystine. The sulfur containing amino acid moiety in glutathione is cysteine. The latter contains a sulfhydryl group. In the former molecule, two cysteine molecules are joined via a disulfide bond.
However, it is not possible to utilize cysteine in compositions for mammals because it is somewhat toxic. Accordingly, in the compositions of this invention, cystine is used. Upon reductive cleavage of the disulfide bridge, two molecules of cysteine are formed. Thus each molecule of cystine is capable of forming two molecules, of cysteine, each of which will join with glutamic acid and glycine to form two molecules of glutathione.
Of course all amino acids employed in this invention, except glycine which does not form optical isomers, are in the natural or L-form.
Although wide variations are possible, it will be apparent that the optimum ratio of glutamic acid to cystine to glycine in the novel compositions described herein is 1:0.5: 1. If an excess of any acid is used, it will presumably be of nutritional value or may simply be metabolized.
As will be apparent to the skilled artisan, the only component in the novel compositions of this invention which may be toxic is selenium. Accordingly, in providing dosage units for mammalian administration by any selected route, the limiting factor is to avoid treatment either with single or multiple dosage units at such levels that the total delivery of selenium is close to its toxic limit.
The recommended daily allowances for elemental selenium as reported in The Pharmacological Basis of Therapeutics, Ninth Edition, page 1540, The McGraw-Hill Companies, 1996 are as follows:
Years ug
Infants 0.0-0.5 10
0.5-1.0 15
Children 1-3 20
4-6 20
 7-10 30
Males 11-14 40
15-18 50
19-24 70
25-50 70
51+ 70
Females 11-14 45
15-18 50
19-24 55
25-50 55
50+ 55
Pregnant — 65
Lactating 1st six months 75
2nd six months 75
The recommended daily dosage for humans therefore ranges from 10 to 75 μg per day. For animals the range may be generally higher but will, of course, depend upon the animal and its size.
The precise amount of the therapeutically useful compositions of this invention for daily delivery and the duration of the period of such delivery will depend upon the professional judgment of the physician or veterinarian in attendance. Numerous factors will be involved in that judgment such as age, body weight, physical condition of the patient or animal and the ailment or disorder being treated.
Selenium is one of numerous trace metals found in many foods. In the compositions of this invention, selenium may be employed as one of several non-toxic, water soluble organic or inorganic selenium compounds capable of being absorbed through the mucosal membrane. The presently preferred inorganic selenium compounds are aliphatic metal salts containing selenium in the form of selenite or selenate anions. However, organic selenium compounds are more preferred because they are normally less toxic than inorganic compounds. Other selenium compounds which may be mentioned by way of example include selenium cystine, selenium methionine, mono- and di-seleno carboxylic acids with about seven to eleven carbon atoms in the chain. Seleno Amino acid chelates are also useful. Any of these selenium compounds may be considered for use in the present invention as selenium precursors.
It is important for the practice of this invention that the selenium as employed in the composition be capable of transport through the mucosal membrane of the patient under treatment. For this reason, water insoluble selenium compounds are not generally useful.
For convenience, the term “selenium” is sometimes used hereinafter to include any of the various water soluble selenium products which can be transported through the mucosal membrane in the practice of this invention. It will be understood, however, that the particular forms of selenium compounds set forth herein are not to be considered limitative. Other selenium compounds, which exhibit the desired activity and are compatible with the other components in the mixture and are non-toxic, can be used in the practice of the invention. Many of them are available commercially.
In fact, the amount of selenium precursor employed in the novel compositions is only enough to provide a catalytic quantity of the element to activate the glutathione system. The catalytic quantity of selenium precursor utilized in the compositions of this invention is such that it will produce either in one dosage unit or in multiple dosage units sufficient elemental selenium to promote the production and activation of glutathione. Typically, this will be at or near the recommended daily allowance of selenium for the individual mammal under treatment. This amount will be well below the toxicity limit for elemental selenium. By way of non-limiting examples, a representative range of catalytic quantities of selenium precursors is set forth in the present application in paragraph [0026] on page 6, as shown to be effective based on the age of the individual.
As indicated above, the presently preferred method of transdermal delivery for the novel compositions is oral, either sublingual or buccal. It is convenient to provide dosage units for such delivery in the form of pills, lozenges or tablets such as gelled tablets which will slowly dissolve in the mouth.
Nasal delivery will typically be accomplished by sprays or drops. Suppositories will be useful for rectal or vaginal delivery.
This invention provides pharmaceutical compositions used in the method of the invention. Such compositions comprise a therapeutically effective amount of combined glutamic acid, cystine, glycine and a selenium precursor in a pharmaceutically acceptable carrier. In a particular embodiment, the term “pharmaceutically acceptable” means one that is generally recognized as safe, approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term “carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the active compounds are administered.
The compositions which may be provided in bulk or dosage unit form are prepared in accordance with standard pharmaceutical practice and may contain excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil may also be useful. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, coloring agents or buffering agents.
Buffering agents are sometimes used in the compositions of the invention to maintain a relatively constant hydrogen ion concentration in the mouth (pH about 7.5) or other point of entry. An appropriate buffering agent may be selected from numerous known reagents including, for example phosphate, carbonate and bicarbonate systems. Alpha-lactalbumin is useful because of its buffering properties. Additionally, it is non-toxic, water soluble and contains appreciable amounts of the required amino acids.
The compositions may also contain mucous membrane penetration enhancers such as sodium lauryl sulphate, sodium dodecyl sulphate, cationic surfactants such as palmitoyl DL camitine chloride, cetylpyridinium chloride, non-ionic surfactants such as polysorbate 80, polyoxyethylene 9-lauryl either, glyceryl monolaurate, polyoxyalkylenes, polyoxyethylene 20 cetyl ether, lipids such as oleic acid, bile salts such as sodium glycocholate, sodium taurocholate and related compounds.
Examples of these suitable carriers are described in Remington's Pharmaceutical Sciences, Nineteenth Edition (1990), Mack Publishing Company, Easton, Pa. in Handbook of Pharmaceutical Excipients, published by The American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (1986) and the Handbook of Water-Soluble Gums and Resins, ed. By R. L. Davidson, McGraw-Hill Book Co., New York, N.Y. (1980). Compositions and methods of manufacturing compositions capable of absorption through the mucosal tissues are taught in U.S. Pat. No. 5,288,497. These publications are incorporated by reference herein in their entirety. They can be readily employed by the skilled artisan to devise methods of delivery other than those specifically described in this disclosure.
The compositions of the invention are most conveniently utilized in dosage units for oral administration. They may be used alone but are preferably provided as tablets, suitably sublingual tablets. Such tablets may be prepared in one a day form or for intermittent use throughout the day, for example every three hours.
The tablets will typically weigh from about 0.5 to 5 grams and will contain a therapeutically effective amount of the essential ingredients together with the selected vehicle. “Therapeutically effective” as used herein means the amount of the composition which is sufficient to achieve the desired result, i.e., enhancement of the immune system. It means that the immune system is more effective in combating infection after treatment than it was before treatment.
A particular advantage of the compositions of the invention is that they can be provided in a number of different forms and at dosage levels appropriate to the individual mammal being treated. For example, tablets, elixers, solutions, emulsions, powders, capsules and other forms can be provided for one a day treatment or successive treatments on the same day for animals or humans whether male or female, whether infant, adolescent or adult. The defining feature of this advantage is the amount of selenium precursor utilized since the other components are essentially non-toxic.
Referring to the table above, tablets and other forms of the immunoenhancing compositions can be prepared to provide any quantity of elemental selenium from less than 1 μg to 7.5 μg. For example, a tablet containing 10 μg of selenium methionine is capable of delivering 4 μg of elemental selenium, and 7.5 μg of selenium methionine is capable of delivering 3 μg of selenium. Tablets may be given several times per day to achieve the desired immune enhancing effect.
A one a day tablet weighing two grams may contain 200 mg or more of the composition. A similar tablet intended to be used every four hours may contain 50 mg to 100 mg or more of the therapeutically effective composition. Equivalent amounts of carrier and active components will be utilized in other compositions designed for other methods of administration.
The following examples are given by way of illustration only and are not to be considered a limitation since many apparent variations are possible without departing from the spirit or scope of the invention.
EXAMPLE 1 (TABLET)
Ingredients:
89 mg cystine
75 mg glycine
147 mg glutamic acid
22.5 μg polyvinylpyrolidone
61.25 mg lactose
4.5 ml alcohol SD3A-200 proof
9 mg stearic acid
42.3 mg corn starch
10 μg selenium methionine
Blend the cystine, glycine, glutamic acid, polyvinylpyrrolidone and lactose together and pass through a 40 mesh screen. Add the alcohol slowly and knead well. Screen the wet mesh through a 4 mesh screen. Dry the granulation at 50 degrees centigrade for 10 hours. Pass the mixture of stearic acid, corn starch and selenium compound through a 60 mesh screen and tumble with the granulation until all the ingredients are well mixed. Compress using a 7/16 inch standard concave punch.
EXAMPLE 2 (TABLET)
Ingredients:
178 mg cystine
150 mg glycine
294 mg glutamic acid
5 μg selenium methionine
126 mg lactose
78 mg potato starch
96 mg ethyl cellulose
54 mg stearic acid
Thoroughly mix the ingredients in a blender, dry, put through a 12 mesh screen and compress into tablet using a 13/32 inch concave punch.

Claims (29)

1. A nutritional or therapeutic composition useful for treatment of mammals to enhance immune activity comprising as the essential active ingredients a catalytic quantity of a selenium source together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine in a molar ratio of about 1:0.5:1, the amount of glutathione precursor being effective to increase the content of glutathione in the body tissue of the mammal above that of a pretreatment level thereby to enhance immune activity.
2. A composition of claim 1 in dosage unit form.
3. A composition of claim 1 in bulk form.
4. A composition of claim 2, wherein the dosage unit is for oral administration.
5. A composition of claim 2, wherein the dosage unit is for nasal administration.
6. A composition of claim 4, wherein the dosage unit is for sublingual administration.
7. A composition of claim 4, wherein the dosage unit is for buccal administration.
8. A composition of claim 1, useful for treating a human.
9. A composition of claim 1 useful for treating an animal.
10. A method of treating a mammal to increase the tissue glutathione concentration in said mammal which comprises treating a mammal in need of such treatment with a therapeutically effective amount of a composition comprising as the essential active ingredients a catalytic quantity of a selenium source together with a glutathione precursor which is a mixture of glutamic acid, cystine and glycine in a molar ratio of about 1:0.5:1.
11. A method of claim 10, wherein the mammal is an animal.
12. A method of claim 10, wherein the mammal is a human.
13. A composition for increasing the level of glutathione in a mammal consisting of:
(A) an anabolic precursor of glutathione, consisting of glutamic acid or a salt, an ester, or an anhydride thereof, cystine or a salt, an ester, or an anhydride thereof and glycine or a salt, an ester, or an anhydride thereof, which collectively convert to glutathione; and
(B) a source of selenium, in an amount that is non-toxic to the mammal on a daily total unit dosage delivery basis; wherein said source of selenium is selenium methionine, selenium cystine, a mono-seleno carboxylic acid with seven to eleven carbon atoms in a chain, or a di-seleno carboxylic acid with seven to eleven carbon atoms in a chain.
14. The composition according to claim 13 in unit dosage form.
15. The composition according to claim 13 in bulk form.
16. The composition according to claim 14 wherein the dosage unit is for oral administration.
17. The composition according to claim 14 wherein the dosage unit is for nasal administration.
18. The composition according to claim 14 wherein the dosage unit is for sublingual administration.
19. The composition according to claim 14 wherein the dosage unit is for buccal administration.
20. The composition according to claim 14 wherein the dosage unit is for anal or vaginal administration.
21. The composition of claim 13 wherein the mammal is a human.
22. The composition of claim 13 wherein one or more of said glutamic acid, cystine, and glycine are in the form of a salt, an ester, or an anhydride thereof.
23. The composition of claim 13 wherein the glutamic acid is in the form of a salt, an ester, or an anhydride thereof.
24. The composition of claim 13 wherein the cystine is in the form of a salt, an ester, or an anhydride thereof.
25. The composition of claim 13 wherein the glycine is in the form of a salt, an ester or an anhydride thereof.
26. The composition according to claim 13, wherein the source of selenium is in a mucosal-membrane transportable form.
27. A method of increasing the level of glutathione in a mammal comprising administering to said mammal an effective amount of a composition consisting of:
(A) an anabolic precursor of glutathione, consisting of glutamic acid or a salt, an ester, or an anhydride thereof, cystine or a salt, an ester, or an anhydride thereof and glycine or a salt, an ester or an anhydride thereof, which collectively convert to glutathione; and
(B) a source of selenium, in an amount that is non-toxic to the mammal on a daily total unit dosage delivery basis; wherein said source of selenium is selenium methionine, selenium cystine, a mono-seleno carboxylic acid with seven to eleven carbon atoms in a chain, or a di-seleno carboxylic acid with seven to eleven carbon atoms in a chain.
28. The method of claim 27 wherein cystine converts to cysteine in the intracellular formation of glutathione.
29. The method of claim 27 wherein the source of selenium provides a unit dosage on an elemental basis of from 1 μg to 7.5 μg of selenium.
US11/371,804 2002-09-23 2006-03-09 Nutritional or therapeutic compositions and methods to increase bodily glutathione levels Expired - Lifetime USRE42645E1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/371,804 USRE42645E1 (en) 2002-09-23 2006-03-09 Nutritional or therapeutic compositions and methods to increase bodily glutathione levels
US13/184,041 US20120029082A1 (en) 2002-09-23 2011-07-15 Nutritional or therapeutic compositions to increase bodily glutathione levels

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/252,957 US6592908B1 (en) 2002-09-23 2002-09-23 Nutritional or therapeutic compositions
US11/181,001 USRE39734E1 (en) 2002-09-23 2005-07-13 Nutritional or therapeutic compositions to increase bodily glutathione levels
US11/371,804 USRE42645E1 (en) 2002-09-23 2006-03-09 Nutritional or therapeutic compositions and methods to increase bodily glutathione levels

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/252,957 Reissue US6592908B1 (en) 2002-09-23 2002-09-23 Nutritional or therapeutic compositions
US11/181,001 Division USRE39734E1 (en) 2002-09-23 2005-07-13 Nutritional or therapeutic compositions to increase bodily glutathione levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/184,041 Continuation US20120029082A1 (en) 2002-09-23 2011-07-15 Nutritional or therapeutic compositions to increase bodily glutathione levels

Publications (1)

Publication Number Publication Date
USRE42645E1 true USRE42645E1 (en) 2011-08-23

Family

ID=22958261

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/252,957 Ceased US6592908B1 (en) 2002-09-23 2002-09-23 Nutritional or therapeutic compositions
US11/181,001 Expired - Lifetime USRE39734E1 (en) 2002-09-23 2005-07-13 Nutritional or therapeutic compositions to increase bodily glutathione levels
US11/371,804 Expired - Lifetime USRE42645E1 (en) 2002-09-23 2006-03-09 Nutritional or therapeutic compositions and methods to increase bodily glutathione levels
US13/184,041 Abandoned US20120029082A1 (en) 2002-09-23 2011-07-15 Nutritional or therapeutic compositions to increase bodily glutathione levels

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/252,957 Ceased US6592908B1 (en) 2002-09-23 2002-09-23 Nutritional or therapeutic compositions
US11/181,001 Expired - Lifetime USRE39734E1 (en) 2002-09-23 2005-07-13 Nutritional or therapeutic compositions to increase bodily glutathione levels

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/184,041 Abandoned US20120029082A1 (en) 2002-09-23 2011-07-15 Nutritional or therapeutic compositions to increase bodily glutathione levels

Country Status (8)

Country Link
US (4) US6592908B1 (en)
EP (2) EP1556023B1 (en)
JP (2) JP5601745B2 (en)
AU (2) AU2003253884A1 (en)
BR (2) BRPI0314666B8 (en)
CA (1) CA2539567C (en)
MX (1) MXPA05003227A (en)
WO (1) WO2004026289A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103478718A (en) * 2013-09-27 2014-01-01 美国东方生物技术（香港）有限公司 Functional food for improving concentration of glutathione in human body and preparation method of functional food
CN103535721A (en) * 2013-09-27 2014-01-29 美国东方生物技术（香港）有限公司 Composition for improving glutathione concentration in human body and preparation method and application thereof
WO2016033183A1 (en) 2014-08-29 2016-03-03 Crum Albert B A method for side effect reduction in the use of statins via physiologically synthesized glutathione
WO2018114749A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with cystine
WO2018114745A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions comprising poorly soluble compounds
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
WO2021219375A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Process of making n,n'-diacetyl-l-cystine
WO2021219378A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Stabilized cosmetic compositions with n, n'-di-acetyl cystine
WO2021219376A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Personal care compositions with enhanced solubility actives
WO2021219377A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Process of making n,n-diacetyl-l-cystine disodium salt from cystine and acetyl chloride in methanol in the presence of sodium hydroxide
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
WO2024052700A1 (en) 2022-09-08 2024-03-14 The Proimmune Company, Llc Compositions to increase glutathione levels and processes for making the same

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040247709A1 (en) * 2003-06-06 2004-12-09 Pro-Health, Inc. Composition and method for treating upper abdominal pain and cramping
WO2005007223A2 (en) * 2003-07-16 2005-01-27 Sasha John Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
FR2879074B1 (en) * 2004-12-15 2007-08-03 Adisseo France Sas Soc Par Act PELLETS OF ACTIVE HYDROPHILIC PRINCIPLE
US20080095826A1 (en) * 2006-10-24 2008-04-24 Hisayuki Uneyama Method of Increasing Peripheral Blood Lymphocytes
WO2016057882A2 (en) * 2014-10-09 2016-04-14 Albert Crum Protective metallothionein analog compounds, their compositions and use thereof in the treatment of pathogenic diseases
JP2019508507A (en) * 2016-03-14 2019-03-28 マイトジェネティクス リミテッド ライアビリティ カンパニー Materials and methods for treating hypoxic conditions
US20200016059A1 (en) * 2016-12-12 2020-01-16 Conopco, Inc., D/Ba Unilever Personal care compositions with glutathione precursor comprising nicotinamide and amino acids
JP2021526127A (en) 2018-05-23 2021-09-30 ユニリーバー・ナームローゼ・ベンノートシヤープ Nanoemulsion and its manufacturing method
WO2022145325A1 (en) * 2020-12-28 2022-07-07 サンスター スイス エスエー Composition for oral cavity

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2292522A (en) 1994-08-22 1996-02-28 Gitta Carmen Conway Multi-vitamin preparation for treatment of the immune system
US5550146A (en) 1992-12-23 1996-08-27 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
RU2096034C1 (en) * 1994-11-30 1997-11-20 Общество с ограниченной ответственностью "Медицинский научно-производственный комплекс "БИОТИКИ" Pharmaceutical composition inducing glutathione biosynthesis, glutathione transferase activity and showing antitoxic, radioprotective and antihypoxic action and methods of treatment, prophylaxis and protection using thereof
US5719133A (en) 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
WO1998015614A1 (en) 1996-10-10 1998-04-16 Life Technologies, Inc. Animal cell culture media comprising plant-derived nutrients
US20010048948A1 (en) 1998-06-10 2001-12-06 Crum Albert B. Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
US6495170B1 (en) 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
JPH0667833B2 (en) * 1985-11-28 1994-08-31 雪印乳業株式会社 Enteral nutrition
US4885157A (en) * 1987-02-13 1989-12-05 Fiaschetti Mary G Dermal cosmetic composition and applications therefor
CA1333471C (en) 1988-04-29 1994-12-13 Gustavo Bounous Whey protein concentrate as food supplement
US5888552A (en) * 1988-04-29 1999-03-30 Immunotec Research Corporation Ltd. Anti-cancer therapeutic compositions containing whey protein concentrate
JP3013871B2 (en) * 1993-10-02 2000-02-28 日本水産株式会社 Method for activating immune activity of marine cultured fish
JPH1149696A (en) * 1997-03-21 1999-02-23 Shiseido Co Ltd Immune activator for preventing hypofunction of ultra-violet skin immunofunction
JPH11292737A (en) * 1998-02-16 1999-10-26 Shiseido Co Ltd Immunopotentiation agent
JP2000245358A (en) * 1999-02-25 2000-09-12 Kohjin Co Ltd Production diet and raising method for salmon and/or trout
AU6768200A (en) * 1999-08-11 2001-03-05 Proimmune Company L.L.C., The Nutritious compositions and food components
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
US5550146A (en) 1992-12-23 1996-08-27 Abbott Laboratories Medical foods for the nutritional support of infant/toddler metabolic diseases
GB2292522A (en) 1994-08-22 1996-02-28 Gitta Carmen Conway Multi-vitamin preparation for treatment of the immune system
US5719133A (en) 1994-09-21 1998-02-17 Novartis Nutrition Ag Adolescent dietary composition
RU2096034C1 (en) * 1994-11-30 1997-11-20 Общество с ограниченной ответственностью "Медицинский научно-производственный комплекс "БИОТИКИ" Pharmaceutical composition inducing glutathione biosynthesis, glutathione transferase activity and showing antitoxic, radioprotective and antihypoxic action and methods of treatment, prophylaxis and protection using thereof
WO1998015614A1 (en) 1996-10-10 1998-04-16 Life Technologies, Inc. Animal cell culture media comprising plant-derived nutrients
US20010048948A1 (en) 1998-06-10 2001-12-06 Crum Albert B. Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
US6495170B1 (en) 2000-08-16 2002-12-17 N. V. Nutricia Method of increasing the presence of glutathione in cells

Non-Patent Citations (79)

* Cited by examiner, † Cited by third party
Title
Basic Medical Biochemistry, Velker, J. (ed.), Williams & Wilkins, Baltimore, 1996, pp. 598-601. *
BIOSIS abstract 2001:509422 (2001). *
Considine, D.M. et al. Van Nostrand's Scientific Encyclopedia, 7th ed., Van Nostrand Reinhold, New York, pp. 128-129 (1989). *
Dale, W.M., et al. A study of the irradiation of catalase by ionizing radiations in the presence of cysteine, crystine and glutathione. Biochem J (1950) 62(1):50-7.
Derwent abstract 1998-320409; abstracting RU 2096034 (1997). *
Guoyao Wu, et al; Gutathione Metabolism . . . for Health; American Society for Nutritional Sciences; 2004; pp. 489-492.
Hideyo Sato et al; Distribution of Cystine/Glutamate . . . Mouse Brain; The Journal of Neuroscience, Sep. 15, 2002; 22(18):8028-8033.
Hutchin, M.E., et al. "Microbiological determination of cystine, systeine, and glutathione in plasma." J Biol Chem (1950) 185(2):839-43.
Juan R. Vina, et al. "Maintenance of GSH Content in Primary Astrocyte Cultures Under Oxidative Stress Conditions" Biochemical Society Transactions (1993) 21:845.
Kenji Miura, et al; Cystine Uptake and . . . Oxidative Stress; The American Physiological Society; 1992; pp. C50-C58.
Martindale The Extra Pharmacopoeia, 30th ed., The Pharmaceutical Press, London, 1993, p. 1047. *
Meier, T., et al. "Promotion of Cyst(e)ine Uptake" Methods Enzymol. (1995) vol. 252, pp. 103-112.
PubMed Abstract 10 Curi, R., et al. "Glutamine-dependent changes in gene expression and protein activity." Cell Biochem Funct. (2005) 23(2):77-84.
PubMed Abstract 123. Wang et al. "Hepatic Export of Glutathione and Uptake of Constituent Amino Acids, Glutamate and Cysteine, in Broilers in Vivo." Poult Sci. (1998) Oct.; 77 (10):1556-1564.
PubMed Abstract 124 Wernerman, J., et al. "Glutathione status in critically-ill patients: possibility of modulation by antioxidants." Proc Nutr Soc. (1999) 58(3):677-80.
PubMed Abstract 137. Tachi et al. "High Concentration of Glucose Causes Impairment of the Function of the Glutathione Redox Cycle in Human Vascular Smooth Muscle Cells." FEBS Lett. (1998) Jan. 2; 421 (1):19-22.
PubMed Abstract 139. Kranich et al. "Utilization of Cysteine and Cysteine Precursors for the Synthesis of Glutathione in Astroglial Cultures: Preference for Cystine." Glia. (1998) Jan.: 22 (1):11-18.
PubMed Abstract 141. Lu, SC. "Regulation of Hepatic Glutathione Synthesis." Semin Liver Dis. (1998) 18(4):331-343.
PubMed Abstract 143. Knickelbein et al. "Characterization of Multiple Cysteine and Cystine Transporters in Rat Alveolar Type II Cells." Am J Physiol. (1997) Dec.; 273(6 Pt 1):L1147-1155.
PubMed Abstract 15 Soh, H., et al. "Glutamine regulates amino acid transport and glutathione levels in a human neuroblastoma cell line." Pediatr Surg Int. (2005) 21(1):29-33.
PubMed Abstract 150. Sayato et al. "Selenium Methylation and Toxicity Mechanism of Selenocystine." Yakugaku Zasshi (1997) Nov.; 117 (10-11):665-672.
PubMed Abstract 159. van Klaveren et al. "Cellular Glutathione Turnover in Vitro, with Emphasis on Type II Pneumocytes." Eur Respir J. (1997) Jun.; 10(6):1392-1400.
PubMed Abstract 160. Froissard et al. "Role of Glutathione Metabolism in the Glutamate-Induced Programmed Cell Death of Neuronal-Like PC12 Cells." Eur J Pharmacol. (1997) May 12;326 (1):93-99.
PubMed Abstract 167. Ochi, T. "Arsenic Compound-Induced Increases in Glutathione Levels in Cultured Chinese Hamster V79 Cells and Mechanisms Associated with Changes in Gamma-Glutamylcysteine Synthetase Activity, Cystine Uptake and Utilization of Cysteine." Arch Toxicol. (1997); 71(12):730-740.
PubMed Abstract 172. Kranich et al. "Different Preferences in the Utilization of Amino Acids for Glutathione Synthesis in Cultured Neurons and Astroglial Cells Derived from Rat Brain." Neurosci Lett. (1996) Nov. 29; 219 (3):211-214.
PubMed Abstract 173. Pan et al. "Increased Uptake of L-Cysteine and L-Cystine by Nerve Growth Factor in Rat Pheochromocytoma Cells." Brian Res. (1996) Nov. 18; 740 (1-2):21-26.
PubMed Abstract 177. Mills et al. "Differential Distribution of Free and Bound Glutathione and Cyst(e)ine in Human Blood." Biochem Pharmacol. (1996) Aug. 9; 52(3):401-406.
PubMed Abstract 180 Denno, R., et al. "Glutamine-enriched total parenteral nutrition enhances plasma glutathione in the resting state." J Surg Res. (1996) 61(1):35-8.
PubMed Abstract 186. Sagara et al. "Glutathione Efflux from Cultures Astrocytes." J Neurochem. (1996) May; 66 (5):1876-1881.
PubMed Abstract 187. Rathbun et al. "Prevention of Acetaminophen- and Naphthalene-Induced Cataract and Glutathione Loss by CySSME." Invest Ophthalmol Vis Sci. (1996) Apr.; 37 (5):923-929.
PubMed Abstract 187. Rathbun et al. "Prevention of Acetaminophen- and Naphthalene-Induced Cataract and Glutathione Loss by CySSME." Invest Ophthalmol Vis Sci. (1996) Apr.; 37 (5):923-929.
PubMed Abstract 193. Deneke et al. "Mechanisms of Use of Extracellular Glutathione by Lung Epithelial Cells and Pulmonary Artery Endothelial Cells." Am J Respir Cell Mol Biol. (1995) Jun.; 12 (6):662-668.
PubMed Abstract 193. Deneke et al. "Mechanisms of Use of Extracellular Glutathione by Lung Epithelial Cells and Pulmonary Artery Endothelial Cells." Am J Respir Cell Mol Biol. (1995) Jun.; 12 (6):662-668.
PubMed Abstract 195. O'Connor et al. "Biosynthesis and Maintenance of GSH in Primary Astrocyte Cultures: Role of L-Cystine and Ascorbate." Brain Res. (1995) May 22; 680 (1-2):157-163.
PubMed Abstract 214. Cotgreave et al. "A Role for Gamma-Glutamyl Transpeptidase in the Transport of Cystine into Human Endothelial Cells: Relationship to Intracellular Glutathione." Biochim Biophys Acta. (1994) Jul. 21; 1222 (3):375-382.
PubMed Abstract 23 Alhamdan, A.A. "The effect of dietary supplementation of N-acetyl-L-cysteine on glutathione concentration and lipid peroxidation in cigarette smoke-exposed rats fed a low-protein diet." Saudi Med J. (2005) 26(2):208-14.
PubMed Abstract 231. Sagara et al. "Maintenance of Neuronal Glutathione by Glial Cells." J Neurochem. (1993) Nov.; 61 (5):1672-1676.
PubMed Abstract 232. Sagara et al. "Cystine Uptake and Glutathione Level in Fetal Brain Cells in Primary Culture and in Suspension." J Neurochem. (1993) Nov.; 61 (5):1667-1671.
PubMed Abstract 238. Vina et al. "Maintenance of GSH Content in Primary Astrocyte Cultures Under Oxidative Stress Conditions." Biochem Soc Trans. (1993) May; 21 (2):84S.
PubMed Abstract 255. Phelps et al. "Elevation of Glutathione Levels in Bovine Pulmonary Artery Endothelial Cells by N-Acetylcysteine." Am J Respir Cell Mol Biol. (1992) Sep.; 7 (3):293-299.
PubMed Abstract 265. Deneke et al. "Endothelial Cell Cystine Uptake and Glutathione Increase with N,N-bis(2-chloroethyl)-N-Nitrosourea Exposure." Am J Physiol. (1992) Mar.; 262 (3 Pt 1):L301-304.
PubMed Abstract 266. Brandi et al. "Differential Effect of the Amino Acid Cystine in Cultured Mammalian and Bacterial Cells Exposed to Oxidative Stress." Mutat Res. (1992) Mar.; 281 (3):157-161.
PubMed Abstract 271. Droge et al. "Modulation of Lymphocyte Functions and Immune Responses by Cysteine and Cysteine Derivatives." Am J Med. (1991) Sep. 30; 91 (3C):140S-144S.
PubMed Abstract 292. Atzori et al. "Growth-Associated Modifications of Low-Molecular-Weight Thiols and Protein Sulfhydryls in Human Bronchial Fibroblasts." J Cell Physiol. (1990) Apr.; 143 (1):165-171.
PubMed Abstract 298. Bannai et al. "Induction of Cystine Transport Activity in Human Fibroblasts by Oxygen." J Biol Chem. (1989) Nov. 5; 264 (31):18480-18484.
PubMed Abstract 309 Wagner, B. "Glutathione in Tetrahymena thermophila." J Protozool (1989) 36(1):92-5.
PubMed Abstract 314 Siegel, D.A., et al. "Effect of pairing in vitro on the glutathione level of male Schistosoma mansoni." J Parasitol (1988) 74(4):524-31.
PubMed Abstract 316 Nygaard, M.E., et al. "Sulfhydryl-related reduction of the mitotic inhibition and cell inactivation induced by pyrimidine analogs." Anticancer Drug Des. (1988) 3(1):15-24.
PubMed Abstract 320 Ishii, T., et al. "Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine." J. Cell Physiol. (1987) 133(2):330-6.
PubMed Abstract 369 Mickelson, M.N., et al. "Cystine antagonism of the antibacterial action of lactoperoxidase-thiocyanate-hydrogen peroxide on Streptococcus agalactiae." Appl Environ Microbiol (1984) 47(2):338-42.
PubMed Abstract 372 Orrenius, S., et al. "Turnover and functions of glutathione studied with isolated hepatic and renal cells." Fed Proc (1983) 42(15):3177-88.
PubMed Abstract 379 Ohmori, H., et al. "Mechanism of augmentation of the antibody response in vitro by 2-mercaptoethanol in murine lymphocytes. II. A major role of the mixed disulfide between 2-mercaptoethanol and cysteine." Cell Immunol (1983) 79(1):173-85.
PubMed Abstract 38 Aliciguzel, Y., et al. "N-acetyl cysteine, L-cysteine, and beta-mercaptoethanol augment selenium-glutathione peroxidase activity in glucose-6-phosphate dehydrogenase-deficient human erythrocytes." Clin Exp Med (2004) 4(1):50-5.
PubMed Abstract 391 Bannai, S., et al. "Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture." Biochim Biophys Acta (1982) 721(1):1-10.
PubMed Abstract 394 Bannai, S., et al. "Transport of cystine and cysteine and cell growth in cultured human diploid fibroblasts: effect of glutamate and homocysteate." J Cell Physiol (1982) 112(2):265-72.
PubMed Abstract 405 Moldeus, P., et al. "Turnover of cellular glutathione in isolated rat-kidney cells. Role of cystine and methionine." Eur J Biochem (1981) 116(1):13-6.
PubMed Abstract 406 Ishii, T., et al. "Mechanism of growth promotion of mouse lymphoma L1210 cells in vitro by feeder layer or 2-mercaptoethanol." J Cell Physiol (1981) 107(2):283-93.
PubMed Abstract 422 Rafter, G.W., et al. "Disulfide-disulfide interchange catalyzed by a liver supernatant enzyme." Biochim Biophys Acta (1979) 567(1):18-23.
PubMed Abstract 44 Evans, M.E., et al. "Glutamine prevents cytokine-induced apoptosis in human colonic epithelial cells." J Nutr. (2003) 133(10):3065-71.
PubMed Abstract 440 Tuttle, S., et al. "Radiation-sensitive tyrosine phosphorylation of cellular proteins: sensitive to changes in GSH content induced by pretreatment with N-acetyl-L-cysteine or L-buthionine-S,R-sulfoximine." Int J Radiat Oncol Biol Phys. (1998) 42(4):833-8.
PubMed Abstract 446 Thompson, G. A., et al. "Utilization of L-cystine by the gamma-glutamyl transpeptidase-gamma-glutamyl cyclotransferase pathway." Proc Nati Acad Sci U S A (1975) 72(6):1985-8.
PubMed Abstract 549 Hou, Y., et al. "Seleno compounds and glutathione peroxidase catalyzed decomposition of S-nitrosothiols." Biochem Biophys Res Commun. (1996) 228(1):88-93.
PubMed Abstract 572 Holleschau, A.M., et al. "An HPLC radiotracer method for assessing the ability of L-cysteine prodrugs to maintain glutathione levels in the cultured rat lens." Curr Eye Res. (1996) 15(5):501-10.
PubMed Abstract 61. Powell et al. "Restoration of Glutathione Levels in Vascular Smooth Muscle Cells Exposed to High Glucose Conditions." Free Radic Biol Med. (2001) Nov. 15; 31 (10):1149-1155.
PubMed Abstract 70 Valencia, E., et al. "Impact of oral L-glutamine on glutathione, glutamine, and glutamate blood levels in volunteers." Nutrition (2002) 18(5):367-70.
PubMed Abstract 74 Yildiz, D. "Inhibition of tumor growth by replacing glutathione with N-acetyl-L-cysteine." Med Hypotheses (2004) 63(1):80-2.
PubMed Abstract 84. Bender et al. "Characterization of Cystine Uptake in Cultured Astrocytes." Neurochem Int. (2000) Aug.-Sep.; 37 (2-3):269-276.
PubMed Abstract 9 Hammarqvist, F., et al. "Free amino acid and glutathione concentrations in muscle during short-term starvation and refeeding." Clin Nutr. (2005) 24(2):236-43.
PubMed Abstract 98 Wu, G., et al. "Glutathione metabolism and its implications for health." J Nutr. (2004) 134(3):489-92.
PubMed Abstract of Deneke SM, et al . Am J Respir Cell Mol Biol. 1995 Jun.; 12(6);662-8.
PubMed Abstract Phelps, DT., et al. Am J Respir Cell Mol Biol. 1992 Sep. 7(3):293-9.
Ralf Dringen, et al; Glutathione Contents as as Indicator . . . Cultures; Journal of Neurochemistry; vol. 67, No. 4; May 19, 1996; pp. 1375-1382.
Schulman, J., et al, "Cystine, Cysteine, and Glutathione Metabolism in Normal and Cystinotic Fibroblasts in Vitro, and in Cultured Normal Amniotic Fluid Cells" Clin. Chim. Acta (1972) 37(53-58).
Shelly C. Lu, Current Topics in Cellular Regulation (2000) 36:95-116.
Shelly C. Lu, The FASEB Journal (1999) 13:1169-1183.
Shiro Bannai; Exchange Of Cystine . . . Fibroblast; The Journal of Biological Chemistry; vol. 261; No. 5; Feb. 15, 1986; pp. 2256-2263.
Thomas Meier, et al. Methods in Enzymology (1995) 252:103-112.
Veber, D.F., et al. "Synthesis of alpha-methyl-DL-g-glutathione." J Med Chm (1967) 10(5):968-9.
Veber, D.G., e al. "Synthesis of alpha-methyl-DL-glutathione." J. Med. Chm. (1967) 10(5): 968-9.

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103478718A (en) * 2013-09-27 2014-01-01 美国东方生物技术（香港）有限公司 Functional food for improving concentration of glutathione in human body and preparation method of functional food
CN103535721A (en) * 2013-09-27 2014-01-29 美国东方生物技术（香港）有限公司 Composition for improving glutathione concentration in human body and preparation method and application thereof
CN103478718B (en) * 2013-09-27 2015-10-28 美国东方生物技术（香港）有限公司 Improve functional food of glutathione concentration in human body and preparation method thereof
CN103535721B (en) * 2013-09-27 2016-04-06 美国东方生物技术（香港）有限公司 Improve composition and method of making the same and the application of glutathione concentration in human body
WO2016033183A1 (en) 2014-08-29 2016-03-03 Crum Albert B A method for side effect reduction in the use of statins via physiologically synthesized glutathione
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
WO2018114749A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with cystine
US10751267B2 (en) 2016-12-21 2020-08-25 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US10980718B2 (en) 2016-12-21 2021-04-20 Conopco, Inc. Personal care compositions comprising poorly soluble compounds
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
US11759412B2 (en) 2016-12-21 2023-09-19 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11666519B2 (en) 2016-12-21 2023-06-06 Conopco, Inc. Personal care compositions with cystine
US11596586B2 (en) 2016-12-21 2023-03-07 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
WO2018114745A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions comprising poorly soluble compounds
US11260005B2 (en) 2016-12-21 2022-03-01 Conopco, Inc. Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
WO2021219377A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Process of making n,n-diacetyl-l-cystine disodium salt from cystine and acetyl chloride in methanol in the presence of sodium hydroxide
WO2021219376A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Personal care compositions with enhanced solubility actives
WO2021219378A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Stabilized cosmetic compositions with n, n'-di-acetyl cystine
WO2021219375A1 (en) 2020-04-28 2021-11-04 Unilever Ip Holdings B.V. Process of making n,n'-diacetyl-l-cystine
WO2024052700A1 (en) 2022-09-08 2024-03-14 The Proimmune Company, Llc Compositions to increase glutathione levels and processes for making the same

Also Published As

Publication number Publication date
WO2004026289A1 (en) 2004-04-01
EP1556023A4 (en) 2010-06-02
JP2012017336A (en) 2012-01-26
US20120029082A1 (en) 2012-02-02
AU2010201136B2 (en) 2013-01-24
MXPA05003227A (en) 2005-08-18
BRPI0314666B1 (en) 2015-12-29
AU2010201136A1 (en) 2010-04-15
CA2539567A1 (en) 2004-04-01
EP1556023B1 (en) 2018-10-17
JP5846822B2 (en) 2016-01-20
AU2003253884A1 (en) 2004-04-08
JP2006502182A (en) 2006-01-19
BRPI0314666B8 (en) 2022-11-22
EP3431080A1 (en) 2019-01-23
US6592908B1 (en) 2003-07-15
EP1556023A1 (en) 2005-07-27
JP5601745B2 (en) 2014-10-08
BR0314666A (en) 2005-08-02
CA2539567C (en) 2013-09-24
USRE39734E1 (en) 2007-07-17

Similar Documents

Publication Publication Date Title
USRE42645E1 (en) Nutritional or therapeutic compositions and methods to increase bodily glutathione levels
US5597585A (en) Vitamin/mineral composition
US20080081796A1 (en) Treatment of mucositis
JP2009242413A (en) Medicine based on amino acid
Grant Nutritional Support in Critically III Patients
US4438144A (en) Amino acid preparation and therapy for treatment of stress and injury
GB2374008A (en) Compositions including copper and their uses
JPH04327537A (en) Method of insuring sufficient intracellular glutathione in tissue
US5747459A (en) Method for insuring adequate intracellular glutathione in tissue
Mitch et al. Effects of oral neomycin and kanamycin in chronic uremic patients: II. Nitrogen balance
JPH08503964A (en) Dietary hypocholesterolemic composition
CA2193396A1 (en) A pharmaceutical composition for the prevention and/or treatment of viral infections and optionally inflammations as well as a method for the treatment thereof
US6605306B1 (en) Food supplement formulation
WO1982000411A1 (en) Novel amino acid preparation and therapy for treatment of stress and injury
US20050256084A1 (en) Antiallergic composition
US20040152665A1 (en) Amelioration of decreased weight and growth by n-acylated glucosamines
WO2022224776A1 (en) Lipid decrease promoter
JP7291380B2 (en) Immediate-acting agent for oral mucosa administration for runny nose or nasal congestion
JPH0710770A (en) Amino acid transfusion solution
US6277883B1 (en) Method of treating male impotence by enhancing the effectiveness of the human immune system
Hall et al. FATAL FAMILIAL FETAL HYPERKERATOSIS
Gray Pharmacology: Vitamins: Nutrients, Food Additives, or Medications Vitamin C
EP1696938A1 (en) Element sulfur as an oral or parental medical product

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 12

SULP Surcharge for late payment

Year of fee payment: 11

AS Assignment

Owner name: THE PROIMMUNE COMPANY, LLC, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CRUM, ALBERT, DR.;REEL/FRAME:060428/0947

Effective date: 20220315